Sensei Biotherapeutics Q1 2024 Earnings Report

Sensei Biotherapeutics EPS Results

• Actual EPS: -$0.32
• Consensus EPS: -$0.29
• Beat/Miss: Missed by -$0.03
• One Year Ago EPS: N/A

Sensei Biotherapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Sensei Biotherapeutics Announcement Details

• Quarter: Q1 2024
• Date: 5/9/2024
• Time: N/A

Sensei Biotherapeutics (NASDAQ:SNSE), an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.